BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...

TransCode Therapeutics named Philippe Calais, Ph.D., as its CEO in a statement to disclose a pair of deals. (Feodora Chiosea/Getty Images) In a pair of deals, TransCode Therapeutics has bagged ...

TransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma Philippe Calais, PharmD, PhD, ...

On Thursday, H.C. Wainwright adjusted its price target on TransCode Therapeutics Inc (NASDAQ: RNAZ) significantly upwards, from $3.00 to $20.00, while maintaining a Buy rating on the stock. This ...

TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. Up Next: Get 5 ...